The U.S. Patent and Trademark Office (USPTO) has issued to Impel NeuroPharma, Inc. a patent relating to the company's POD™ device. Patent number 9,550,036, entitled "NASAL DRUG DELIVERY DEVICE," is directed to a device for delivery of compounds to the nasal cavity and methods of using the same.   Impel is...

March 03, 2017 05:00 AM Eastern Standard Time SEATTLE--(BUSINESS WIRE)--Impel NeuroPharma, a Seattle-based clinical-stage biotechnology company developing first-in-class intranasal drug treatments, announced today the appointment of Timothy S. Nelson as Independent Director of the Board of Directors. Mr. Nelson has over 20 years of experience with drug delivery, medical devices and drug...

SEATTLE, Feb. 7, 2017 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based clinical stage biotechnology company developing first-in-class intranasal drug treatments announced today that it has entered into service agreements with Camargo Pharmaceutical Services, LLC. Camargo will be providing end-to-end regulatory consulting and strategic development services for Impel's pipeline of drug-device combination...

Development of neurological and mental health drugs often requires pre-clinical testing in multiple pre-clinical models to demonstrate efficacy and safety and to elucidate mechanisms. Drug delivery to the central nervous system (CNS) to target neurological diseases is particularly problematic because the blood-brain barrier (BBB) prevents most compounds from reaching the...

The Centre for Addiction and Mental Health (CAMH) and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression. This novel treatment is a peptide that disrupts two dopamine receptors that bind at higher rates in the brains of people...

Stop by at SFN to see Impel’s Device in Poster Presentations Be sure to check out these poster presentations featuring the POD devices at SFN 2015 in Chicago this week! Monday, October 19, 2015 1:00 pm – 5:00 pm McCormick Place Hall A | Program#/Poster#: 395.18/D39 L Tan, Ph.D., Salk Institute Intranasal administration of a small molecule...

SEATTLE, Wash., October 30, 2014 – Impel NeuroPharma is pleased toannounce that H. Stewart Parker, a prominent leader in Seattle’s Biotechnology community, has joined Impel’s Board of Directors. Most recently, Parker was the CEO of the Seattle-based Infectious Disease Research Institute (IDRI), a nonprofit global health research institute developing diagnostics, vaccines,...